Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study

Leuk Lymphoma. 2017 Nov;58(11):2738-2740. doi: 10.1080/10428194.2017.1307360. Epub 2017 Apr 12.

Authors

Sara Grammatico¹, Sara Bringhen², Federico Vozella¹, Agostina Siniscalchi³, Mario Boccadoro², Maria Teresa Petrucci¹

Affiliations

¹ a Hematology Service, Department of Cellular Biotechnology and Hematology , ' Sapienza' University , Rome , Italy.
² b Department of Hematology , University of Torino , Turin , Italy.
³ c Department of Hematology , S. Eugenio Hospital , Rome , Italy.

PMID: 28402163
DOI: 10.1080/10428194.2017.1307360

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Multicenter Study

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bortezomib / administration & dosage
Disease Progression
Drug Resistance, Neoplasm
Female
Humans
Male
Melphalan / administration & dosage
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Multiple Myeloma / pathology*
Prednisone / administration & dosage
Recurrence
Survival Analysis
Treatment Outcome

Substances

Bortezomib
Melphalan
Prednisone